Medtronic Resolute Onyx 2.0 mm Clinical Study | NCT02412501

Label	Type	Description	Intervention Names
Device	Other	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent	Device: Resolute Onyx Stent - 2.0 mm

Name	Type	Description	Arm Group Labels	Other Names
Resolute Onyx Stent - 2.0 mm	Device	Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent	Device

Measure	Description	Time Frame
Number of Participants With Target Lesion Failure at 12 Months Post-Procedure	Target Lesion Failure at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (Q wave or non-Q wave) or Target Lesion Revascularization by percutaneous or surgical methods.	12 Months

Measure	Description	Time Frame
Number of Participants With Cardiac Death at 12 Months Post Procedure		12 Months
Number of Participants With Target Vessel Myocardial Infarction (TVMI) at 12 Months Post Procedure	TVMI defined as Q Wave or non-Q Wave MI

Name	Affiliation	Role
Matthew J. Price, MD, FACC, FSCAI	Scripps Green Hospital	Principal Investigator
Shigeru Saito, MD	Shonan Kamakura General Hospital	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Scripps Green Hospital		La Jolla	California	92037	United States
Morton Plant Hospital

PubMed Identifier	Type	Citation	Retractions
28728650	Derived	Price MJ, Saito S, Shlofmitz RA, Spriggs DJ, Attubato M, McLaurin B, Popma Almonacid A, Brar S, Liu M, Moe E, Mehran R. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. JACC Cardiovasc Interv. 2017 Jul 24;10(14):1381-1388. doi: 10.1016/j.jcin.2017.05.004.

ID	Title	Description
FG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Stent System > > Resolute Onyx Stent - 2.0 mm

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Mar 26, 2015	Feb 9, 2018

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Number of Participants With Target Lesion Failure at 12 Months Post-Procedure

Target Lesion Failure at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (Q wave or non-Q wave) or Target Lesion Revascularization by percutaneous or surgical methods.

Posted

Count of Participants

Participants

12 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title

Denominators

Categories

Title	Measurements
	OG0005

Secondary

Number of Participants With Cardiac Death at 12 Months Post Procedure

Posted

Count of Participants

Participants

12 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators	Categories

Secondary

Number of Participants With Target Vessel Myocardial Infarction (TVMI) at 12 Months Post Procedure

TVMI defined as Q Wave or non-Q Wave MI

Posted

Count of Participants

Participants

12 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Secondary

Number of Participants With a Major Adverse Cardiac Event at 12 Months Post Procedure

Posted

Count of Participants

Participants

12Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Target Lesion Failure (TLF) at 24 Months Post Procedure

Posted

Count of Participants

Participants

24 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Target Vessel Failure (TVF) at 12 Months Post Procedure

Posted

Count of Participants

Participants

12 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Stent Thrombosis (ST) at 12 Months Post Procedure

Posted

Count of Participants

Participants

12 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Cardiac Death at 24 Months Post Procedure

Posted

Count of Participants

Participants

24 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators	Categories

Secondary

Number of Participants With Target Vessel Myocardial Infarction (TVMI) at 24 Months Post Procedure

TVMI defined as Q Wave or non-Q Wave MI

Posted

Count of Participants

Participants

24 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Secondary

Number of Participants With a Major Adverse Cardiac Event at 24 Months Post Procedure

Posted

Count of Participants

Participants

24 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Target Vessel Failure (TVF) at 24 Months Post Procedure

Posted

Count of Participants

Participants

24 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Stent Thrombosis (ST) at 24 Months Post Procedure

Posted

Count of Participants

Participants

24 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Target Lesion Failure (TLF) at 36 Months Post Procedure

Posted

Count of Participants

Participants

36 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Cardiac Death at 36 Months Post Procedure

Posted

Count of Participants

Participants

36 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators	Categories

Secondary

Number of Participants With Target Vessel Myocardial Infarction (TVMI) at 36 Months Post Procedure

TVMI defined as Q Wave or non-Q Wave MI

Posted

Count of Participants

Participants

36 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Secondary

Number of Participants With a Major Adverse Cardiac Event at 36 Months Post Procedure

Posted

Count of Participants

Participants

36 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Target Vessel Failure (TVF) at 36 Months Post Procedure

Posted

Count of Participants

Participants

36 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Secondary

Number of Participants With Stent Thrombosis (ST) at 36 Months Post Procedure

Posted

Count of Participants

Participants

36 Months

ID	Title	Description
OG000	Device	Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent > > Resolute Onyx Stent - 2.0 mm: Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent

Units	Counts
Participants	OG000101

Title	Denominators

Serious Adverse Events

Term	Organ System	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Haemorrhagic Anaemia	Blood and lymphatic system disorders	Systematic Assessment	EG0003 events3 affected101 at risk
Pancytopenia	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Acute Coronary Syndrome	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Acute Left Ventricular Failure	Cardiac disorders	Systematic Assessment	EG0003 events3 affected101 at risk
Acute Myocardial Infarction	Cardiac disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Angina Pectoris	Cardiac disorders	Systematic Assessment	EG0003 events3 affected101 at risk
Angina Unstable	Cardiac disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Anginal Equivalent	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Arrhythmia	Cardiac disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Arteriosclerosis Coronary Artery	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Atrial Fibrillation	Cardiac disorders	Systematic Assessment	EG0003 events2 affected101 at risk
Atrial Flutter	Cardiac disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Atrial Tachycardia	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Cardiac Aneurysm	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Cardiomyopathy	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Coronary Artery Disease	Cardiac disorders	Systematic Assessment	EG00012 events11 affected101 at risk
Coronary Artery Stenosis	Cardiac disorders	Systematic Assessment	EG0007 events5 affected101 at risk
Myocardial Ischaemia	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Sinus Bradycardia	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Ventricular Tachycardia	Cardiac disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Vertigo	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Vertigo Positional	Ear and labyrinth disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Adrenal Insufficiency	Endocrine disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Cataract	Eye disorders	Systematic Assessment	EG0002 events1 affected101 at risk
Eye Swelling	Eye disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Diarrhoea	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Diverticulum Intestinal Haemorrhagic	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Dysphagia	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Gastric Perforation	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Gastric Ulcer	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Gastrointestinal Haemorrhage	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Inguinal Hernia	Gastrointestinal disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Irritable Bowel Syndrome	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Large Intestine Perforation	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Large Intestine Polyp	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Nausea	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Oesophagitis	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Pancreatitis Acute	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Chest Discomfort	General disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Chest Pain	General disorders	Systematic Assessment	EG0006 events5 affected101 at risk
Chills	General disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Non-Cardiac Chest Pain	General disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Pyrexia	General disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Vascular Stent Stenosis	General disorders	Systematic Assessment	EG0007 events6 affected101 at risk
Biliary Colic	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Cholecystitis	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Cholecystitis Acute	Hepatobiliary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Bronchitis Bacterial	Infections and infestations	Systematic Assessment	EG0003 events2 affected101 at risk
Clostridium Difficile Colitis	Infections and infestations	Systematic Assessment	EG0002 events2 affected101 at risk
Colon Gangrene	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Diverticulitis	Infections and infestations	Systematic Assessment	EG0002 events2 affected101 at risk
Extradural Abscess	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Influenza	Infections and infestations	Systematic Assessment	EG0002 events2 affected101 at risk
Osteomyelitis	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Pneumonia	Infections and infestations	Systematic Assessment	EG0008 events4 affected101 at risk
Pneumonia Mycoplasmal	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Post Procedural Infection	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Sepsis	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Sepsis Syndrome	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Staphylococcal Sepsis	Infections and infestations	Systematic Assessment	EG0001 events1 affected101 at risk
Urinary Tract Infection	Infections and infestations	Systematic Assessment	EG0006 events3 affected101 at risk
Cartilage Injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected101 at risk
Fall	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected101 at risk
Osteoradionecrosis	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected101 at risk
Plaque Shift	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events2 affected101 at risk
Subdural Haematoma	Injury, poisoning and procedural complications	Systematic Assessment	EG0002 events1 affected101 at risk
Transplant Failure	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected101 at risk
Traumatic Haemorrhage	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected101 at risk
Traumatic Renal Injury	Injury, poisoning and procedural complications	Systematic Assessment	EG0001 events1 affected101 at risk
Haematocrit Decreased	Investigations	Systematic Assessment	EG0001 events1 affected101 at risk
Haemoglobin Decreased	Investigations	Systematic Assessment	EG0001 events1 affected101 at risk
Troponin Increased	Investigations	Systematic Assessment	EG0001 events1 affected101 at risk
Hyperglycaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Hypokalaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Hypomagnesaemia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Hyponatraemia	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Type 2 Diabetes Mellitus	Metabolism and nutrition disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Back Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Musculoskeletal Pain	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Rotator Cuff Syndrome	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Spinal Osteoarthritis	Musculoskeletal and connective tissue disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Cholangiocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Malignant Melanoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Oral Neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Oropharyngeal Cancer Recurrent	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Prostate Cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Small Cell Lung Cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Squamous Cell Carcinoma Of The Oral Cavity	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Transitional Cell Carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Systematic Assessment	EG0001 events1 affected101 at risk
Aphasia	Nervous system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Carotid Artery Stenosis	Nervous system disorders	Systematic Assessment	EG0003 events3 affected101 at risk
Cerebrovascular Accident	Nervous system disorders	Systematic Assessment	EG0003 events3 affected101 at risk
Dizziness	Nervous system disorders	Systematic Assessment	EG0002 events1 affected101 at risk
Encephalopathy	Nervous system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Ischaemic Stroke	Nervous system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Presyncope	Nervous system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Radiculopathy	Nervous system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Sciatica	Nervous system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Seizure	Nervous system disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Syncope	Nervous system disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Transient Ischaemic Attack	Nervous system disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Device Occlusion	Product Issues	Systematic Assessment	EG0001 events1 affected101 at risk
Agitation	Psychiatric disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Acute Kidney Injury	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Bladder Outlet Obstruction	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Chronic Kidney Disease	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Haematuria	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Nephrolithiasis	Renal and urinary disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Nephropathy Toxic	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Renal Cortical Necrosis	Renal and urinary disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Acute Respiratory Distress Syndrome	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Acute Respiratory Failure	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0006 events2 affected101 at risk
Asthma	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Chronic Obstructive Pulmonary Disease	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG00010 events4 affected101 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Haemoptysis	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Pneumothorax	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Pulmonary Mass	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Respiratory Acidosis	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Respiratory Failure	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0005 events4 affected101 at risk
Erythema	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Urticaria	Skin and subcutaneous tissue disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Aortic Aneurysm	Vascular disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Hypertensive Crisis	Vascular disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Hypertensive Emergency	Vascular disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Hypotension	Vascular disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Intermittent Claudication	Vascular disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Orthostatic Hypotension	Vascular disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Peripheral Arterial Occlusive Disease	Vascular disorders	Systematic Assessment	EG0002 events2 affected101 at risk
Peripheral Artery Aneurysm	Vascular disorders	Systematic Assessment	EG0001 events1 affected101 at risk
Peripheral Vascular Disorder	Vascular disorders	Systematic Assessment	EG0002 events2 affected101 at risk

ID	Term
D003327	Coronary Disease
D017202	Myocardial Ischemia
D006331	Heart Diseases
D002318	Cardiovascular Diseases
D001161	Arteriosclerosis
D001157	Arterial Occlusive Diseases
D014652	Vascular Diseases